Spring bank pharmaceuticals, inc. (SBPH)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-8,178

-7,435

-6,912

-4,555

-5,195

-5,425

-8,780

-3,785

-4,864

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-10,828

-8,889

-6,500

-2,400

-4,147

-4,301

-6,518

-3,946

-3,397

-2,263

-1,958

Adjustments for:
Depreciation and amortization

96

94

92

88

83

95

107

41

45

43

39

40

36

31

30

31

26

27

27

21

13

Operating lease right-of-use asset amortization

69

67

66

65

65

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

-239

-151

-355

-4,885

-2,821

-780

1,336

-3,971

-1,202

-4,679

5,780

3,667

2,027

-

-

-

-

-

-

-

-

Non-cash interest expense

77

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investment income

-

-

-

-

-

-

-

-

-

-

-

-25

-25

-

-

-

-

-

-

-

-

Non-cash investment expense

127

-32

132

-84

12

-

-251

-75

-35

-

-

-

-

-

-

-

-15

-

-

-

-

Non-cash stock-based compensation

817

542

812

1,041

972

714

713

691

658

428

510

473

500

423

378

335

302

432

433

147

113

Non-cash issuance of common stock and warrants connected to license agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,780

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-561

1,795

-675

1,184

-431

620

-176

596

29

-270

-34

403

-359

-219

55

-111

802

693

79

-44

4

Other assets

-

0

0

-163

31

-

-

-

181

-

-

-

-

0

0

0

35

-

-

-

-

Accounts payable

-218

-776

1,261

-261

106

506

-314

33

-45

-73

-178

-87

519

-960

712

276

-840

1,666

-43

221

-9

Accrued expenses and other liabilities

44

440

-1,163

1,492

-411

-1,303

1,160

543

-605

421

873

519

-1,081

516

263

-742

460

-

-

-

-

Operating lease liabilities

-83

-

-

-

26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-7,181

-8,584

-5,706

-7,978

-6,787

-6,887

-5,397

-6,772

-6,188

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Accrued expenses and other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

645

419

-149

122

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-4,115

-4,111

-2,812

-4,284

-4,612

-1,869

-2,640

-1,979

-1,723

Proceeds from sale of marketable securities

15,077

12,003

9,980

7,903

8,884

6,032

6,886

8,401

13,550

7,709

2,892

3,999

7,714

3,790

1,378

1,251

2,265

-

-

-

-

Purchases of marketable securities

6,000

-

-

-

-

8,000

28,000

12,000

10,000

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

2

64

3

134

71

59

919

744

250

196

23

4

100

57

3

56

97

65

20

280

24

Net cash provided by investing activities

9,075

2,939

9,977

1,769

8,813

-2,027

-22,033

-4,343

3,300

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

7,614

-4,552

-2,037

-2,086

2,168

-903

-841

-7,163

-24

Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

21,648

Proceeds from issuance of common stock in connection with at-the-market offering, net of issuance costs

30

-

-

-

-

0

-1

386

2,827

-

-

-

-

-

-

-

-

-

-

-

-

Payment of finance costs related to issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,754

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

25

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

0

0

90

2

-

-

-

-

-

-

-

-

Issuance costs paid in connection with the private investment in a public entity

-

-

-

-

-

-

-

-

-

-

-

38

147

-

-

-

-

-

-

-

-

Cash provided by financing activities

30

-

-

-

-

1

37,958

386

2,827

-

-

-

-

-

-

-

-

-

-

-

-

Cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-145

-

-

-

-

0

0

0

19,919

Net increase in cash, cash equivalents and restricted cash

1,924

-5,662

23,824

-6,203

2,026

-8,913

10,528

-10,729

-61

6,344

-33,654

37,405

3,354

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,423

-2,444

-2,772

-3,481

-9,142

18,172

Supplemental disclosures of cash flow information:
Cash paid for taxes

-

-

-

-

-

0

0

0

3

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest, net

403

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-